Get started
META on a new expansion wave to $800.Meta Platforms / META is pulling back again to test the 1day MA50, which has been holding since September 11th. The pattern is quite similar to the January 2nd 2024 pull back, a bullish break out that also took place after a prolonged consolidation pattern. The 1week RSI patterns between the two are also fairly similar. As long as the 1day MA50 holds, we expect META to stay on this expansion wave. Target $800 which is a +93.92% rise from the bottom, the rise that formed the previosu peak (April 8th 2024). Previous chart: Follow us, like the idea and leave a comment below!!
NASDAQ:METALong
by TheCryptagon
Marathon Digital Holdings (MARA) AnalysisCompany Overview: Marathon Digital Holdings NASDAQ:MARA is a key player in the cryptocurrency mining sector, particularly focused on Bitcoin production. The company has shown resilience and operational strength in its mining activities, making it well-positioned for future growth. Key Developments: Positive Analyst Ratings: Analysts from Macquarie and Cantor Fitzgerald have set price targets above $20, indicating strong growth potential for Marathon Digital. This reflects growing confidence in the company's operational and market strategies. Increased Bitcoin Production: In September 2024, Marathon reported a 5% increase in Bitcoin production, reinforcing its operational strength. Additionally, the company achieved a 28% increase in Q1 2024 production, yielding 2,811 BTC compared to the same quarter in 2023. This efficiency in production underlines Marathon’s capacity to scale effectively in a competitive market. Favorable Cryptocurrency Market: With Bitcoin recently surpassing $67,000, the broader cryptocurrency market is showing favorable conditions. This surge allows MARA to capitalize on increased investor interest in crypto stocks, positioning the company for substantial market gains. Investment Outlook: Bullish Outlook: We are bullish on MARA above the $16.00-$17.00 range, driven by the company’s production efficiency and favorable market conditions. Upside Potential: Our target for Marathon Digital is set at $32.00-$33.00, supported by positive analyst sentiment and operational achievements. 🚀 MARA—Mining for Tomorrow's Success! #Cryptocurrency #BitcoinMining #GrowthPotential
NASDAQ:MARALong
by Richtv_official
Celsius ($CELH) is FINALLY BOTTOMING. NOW IS THE TIME TO BUY! NASDAQ:CELH is FINALLY BOTTOMING?! NOW IS THE TIME TO BUY! 5 REASONS WHY: 1⃣ We have DIVERGENCE on the Weekly Chart 2⃣ It's a "High Five Setup" 3⃣ It's a BUY according to my Valuation Metric Tool (4/6 score) 4⃣ Growth Beast! Beaten down over 40% this year 5⃣ Find out by watching. 👇 Video analysis 5/5. Stay tuned for more!🔔 Like ❤️ Follow 🤳 Share 🔂 Will Celsius finally get back on track with their growth or be defeated by the Goliath Monster?! Sorry for the pauses in the middle of the video; my dog came in and was about to start howling 🐶🤣 Not financial advice.
NASDAQ:CELHLong
by RonnieV29
4
Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio but also opens up new revenue channels for the company. Key Developments: Strong Revenue Generation: Argenx demonstrates a robust global presence with revenue streams across various regions: U.S.: $407 million Japan: $20 million EMEA: $35 million China: $14 million This diversified revenue generation helps mitigate regional risks and showcases the company’s ability to penetrate multiple markets effectively. Upcoming Trials: The company plans to launch four new registration trials by the end of 2024, further expanding its therapeutic offerings. This proactive approach to research and development positions Argenx for future growth and diversification in its product line. Strategic Collaboration: Argenx's collaboration with Monarch is aimed at enhancing operational efficiency and customer service. This partnership is expected to boost market penetration and strengthen the company's competitive edge. Investment Outlook: Bullish Outlook: We are bullish on ARGX above the $484.00-$489.00 range, driven by its recent FDA approval, diverse revenue streams, and plans for further clinical expansion. Upside Potential: Our target for Argenx is set at $740.00-$750.00, supported by the company’s strong market presence and growth initiatives. 🚀 ARGX—Pioneering the Future of Autoimmune Treatments. #Biotech #AutoimmuneTherapy #MarketGrowth
NASDAQ:ARGXLong
by Richtv_official
$SOUN :Is Sound Hound AI the next small cap to SURGE?! 98% move!NASDAQ:SOUN Is Sound Hound AI the next small cap to SURGE?! I believe this stock is gearing up for a 98% move higher! So, let's dive into my video below, which talks about the NASDAQ:SOUN stock charting setup for a SURGE to the upside and how it meets my 5/5 trading setup! (My personal trading strategy) Not financial advice. Like ❤️ Follow🤳 Share 🔂 Comment what stock you want to see charting analysis on below.
Editors' picks
NASDAQ:SOUNLong
by RonnieV29
24